^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 765179

    i
    Other names: BI 765179, BI-765179, BI765179
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    CD137 agonist, FAP inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=160, Recruiting, Boehringer Ingelheim | Trial completion date: Jan 2027 --> Nov 2028 | Trial primary completion date: Apr 2026 --> Aug 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • ezabenlimab (BI 754091) • BI 765179
    11ms
    A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=160, Recruiting, Boehringer Ingelheim | Trial completion date: Mar 2026 --> Nov 2026 | Trial primary completion date: Jun 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ezabenlimab (BI 754091) • BI 765179
    over1year
    A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=160, Suspended, Boehringer Ingelheim | Recruiting --> Suspended
    Trial suspension • Combination therapy • Metastases
    |
    FAP (Fibroblast activation protein, alpha)
    |
    ezabenlimab (BI 754091) • BI 765179
    over1year
    A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=160, Recruiting, Boehringer Ingelheim | Trial completion date: Jul 2025 --> May 2026 | Trial primary completion date: Sep 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    FAP (Fibroblast activation protein, alpha)
    |
    ezabenlimab (BI 754091) • BI 765179
    over2years
    A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=150, Recruiting, Boehringer Ingelheim | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    FAP (Fibroblast activation protein, alpha)
    |
    ezabenlimab (BI 754091) • BI 765179
    3years
    A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=150, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    FAP (Fibroblast activation protein, alpha)
    |
    ezabenlimab (BI 754091) • BI 765179
    over3years
    A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Boehringer Ingelheim
    Clinical • New P1 trial • Combination therapy
    |
    FAP (Fibroblast activation protein, alpha)
    |
    ezabenlimab (BI 754091) • BI 765179